One might extrapolate from these findings that acute prophylactic pharmacologic inhibition of ALK2 activity could be sufficient to prevent HO in individuals with FOP, although the specific window of time during which transient therapy is effective would need to be determined in humans. The gene discussed is ACVR1; the disease is fibrodysplasia ossificans progressiva.